Patents by Inventor Prasada Rao Jalagam

Prasada Rao Jalagam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors
    Patent number: 11970511
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 30, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Substituted bicyclic compounds useful as T cell activators
    Patent number: 11964973
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
  • COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR
    Publication number: 20240108654
    Abstract: Provided herein are methods, compositions and uses involving T cell therapies, such as adoptive T cell therapy, and an inhibitor of a Diacylglycerol kinase (DGK). The provided methods, compositions and uses include those involving the administration or use of one or more DGK inhibitors (DGKi) in a combination therapy with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR) or T cell receptor (TCR).
    Type: Application
    Filed: March 2, 2022
    Publication date: April 4, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: David G. KUGLER, Jim QIN, Alison MAIER, Richard OLSON, Michael WICHROSKI, Upender VELAPARTHI, Chetan Padmakar DARNE, Bireshwar DASGUPTA, Denise Christine GRUNENFELDER, Jayakumar Sankara WARRIER, Hasibur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Pallavur SIVAKUMAR
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 11713316
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 1, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20230212158
    Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: May 10, 2021
    Publication date: July 6, 2023
    Inventors: Prasada Rao Jalagam, Susheel Jethanand Nara, Manoranjan Panda, Murugesan Natesan, Pratik Devasthale
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20230192672
    Abstract: The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 22, 2023
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Susheel Jethanand Nara, Manoranjan Panda, Pratik Devasthale, Alicia Regueiro-Ren
  • SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230151007
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 18, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230086933
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 23, 2023
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Richard E. Olson, Prasada Rao Jalagam, Jayakumar Sankara Warrier
  • COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS
    Publication number: 20230089255
    Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 23, 2023
    Inventors: Susan WEE, Joseph L. BENC, Xinyu WANG, Upender VELAPARTHI, Louis S. CHUPAK, Chatan P. DARNE, Min DING, Robert G. GENTLES, Yazhong HUANG, Scott W. MARTIN, Ivar M. MCDONALD, Richard E. OLSON, Xiaofan ZHENG, John S. TOKARSKI, Bireshwar DASGUPTA, Manjunatha Narayana Rao KAMBLE, Raju MANNOORI, Haslbur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Gopikishan TONUKUNURU, Sivasudar VELAIAH, Jayakumar Sankara WARRIER, Kotha Rathnakar REDDY, Thiruvenkadam RAJA, Denise GRUNENFELDER, Michael WICHROSKI
  • Substituted pyridopyrimidinonyl compounds useful as T cell activators
    Patent number: 11584747
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: February 21, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20220324859
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: October 13, 2022
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20220144818
    Abstract: The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: April 8, 2020
    Publication date: May 12, 2022
    Inventors: Chunjian Liu, Jianxin Feng, Pratik Devasthale, Natesan Murugesan, Bruce A. Ellsworth, Alicia Regueiro-Ren, Susheel Jethanand Nara, Prasada Rao Jalagam, Manoranjan Panda
  • Small molecule inhibitors of galectin-3
    Patent number: 11267811
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth Sarabu, Jacob Swidorski, Brett R. Beno, Alicia Regueiro-Ren
  • TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS
    Publication number: 20210323991
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 21, 2021
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Small molecule inhibitors of Galectin-3
    Patent number: 11072626
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: July 27, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Alicia Regueiro-Ren
  • SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20210188845
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 24, 2021
    Inventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20210147408
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: September 27, 2018
    Publication date: May 20, 2021
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth SARABU, Jacob SWIDORSKI, Brett R. BENO, Alicia Regueiro-Ren
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 10954238
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20210061802
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 4, 2021
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20200308213
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: October 10, 2018
    Publication date: October 1, 2020
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Alicia Regueiro-Ren